Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation
About this study
The study aims to validate the Decipher® genomic test, in which patients with biochemical recurrence after radical prostatectomy are treated with salvage radiotherapy with extreme hypofractionation (5+ Gy/fraction). Validating the Decipher® genomic classifier based on the expression of 22 RNA genes in the prospective study "esSBRT"
- Condition
- Prostatic Neoplasms
- Sponsor
- Regina Elena Cancer Institute
Who can join
- Age
- Not specified
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 4
- Eligible sex: Male
- Study condition: Prostatic Neoplasms
- patients enrolled at IRE under the "esSBRT" protocol (meeting the criteria of the same);
- patients who express written informed consent personally or through their legal representative/witness/curator/guardian/support administrator (participation in the ancillary study and data processing)
Exclusion 1
- all exclusion criteria adopted for the "esSBRT" study.
Where
1 site, 1 recruiting
IRCSS Regina Elena
Roma, Italy
Contact
-
Giuseppe Sanguineti, Doctor
+39-06 52663010 giuseppe.sanguineti@ifo.it
Potential match only. Final eligibility is determined by the study team.